You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


EMA ends rolling review for COVID antibodies

The EMA have stopped a rolling review of the marketing authorisation application for the antibodies bamlanivimab and etesevimab by Eli Lilly Netherlands, to treat COVID-19.